IA
CMPX icon

IFP Advisors’s Compass Therapeutics CMPX Stock Holding History

IFP Advisors’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6
Closed -$32 – 5166
2026
Q1 		$32 Hold
6
– – ﹤0.01% 4881
2025
Q4 		$32 Hold
6
– – ﹤0.01% 4754
2025
Q3 		$21 Buy
+6
New +$19 ﹤0.01% 4752
2025
Q2 		– Sell
-16
Closed -$30 – 4937
2025
Q1 		$30 Hold
16
– – ﹤0.01% 4113
2024
Q4 		$23 Buy
+16
New +$27 ﹤0.01% 4429

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

IFP Advisors's CMPX Position: Q2 2026 in Review

IFP Advisors sold out of Compass Therapeutics (CMPX) in Q2 2026, closing a stake of 6 shares — an estimated $32 sold.

IFP Advisors first reported a position in CMPX in Q4 2024 and held it in 5 quarters. The position peaked at $32 in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • IFP Advisors reported no remaining Compass Therapeutics position as of Q2 2026 after selling out during the quarter.
  • IFP Advisors sold 6 Compass Therapeutics shares in Q2 2026, an estimated $32.
  • IFP Advisors first reported a position in Compass Therapeutics in Q4 2024 and held it in 5 quarters.
  • IFP Advisors's Compass Therapeutics position peaked at $32 in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.